RxDoctor Payments Data

Sean-Adam le, MD

Internal Medicine · Chicago, ILNPI 1578552915

Payments from drug & device makers

$12,994in general payments, 2019–2025

Across 525 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$5K
  • Novo Nordisk$1K
  • Pfizer$709
  • AbbVie$571
  • Boehringer Ingelheim$555
  • Amgen$522
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$3,39026%
  • Food & beverage$9,56774%
  • Education$200%
  • Gifts$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,994 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$174,102
Medicare patients
254
Services billed
2,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin328$267,952
VemlidyTenofovir Alafenamide79$128,056
JanuviaSitagliptin Phosphate106$118,325
FarxigaDapagliflozin Propanediol120$102,381
RybelsusSemaglutide84$101,907
TradjentaLinagliptin95$90,040
BiktarvyBictegrav/Emtricit/Tenofov Ala11$51,050
OzempicSemaglutide22$41,837
MyrbetriqMirabegron48$39,162
EliquisApixaban26$35,347
KerendiaFinerenone35$33,766
BelsomraSuvorexant47$20,955
XareltoRivaroxaban17$20,882
ProliaDenosumab12$20,702
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$17,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$555$363,346434 claims
GileadVemlidy, Biktarvy$4,687$179,10690 claims
Novo NordiskRybelsus, Ozempic$1,448$143,744106 claims
MerckJanuvia, Belsomra$398$139,280153 claims
AstraZenecaFarxiga$498$102,381120 claims
Astellas Pharma US IncMyrbetriq$65$39,16248 claims
PfizerEliquis$709$35,34726 claims
BayerKerendia$405$33,76635 claims
Johnson & JohnsonXarelto$322$20,88217 claims
AmgenProlia$522$20,70212 claims
Sumitomo Pharma America, Inc.Gemtesa$193$16,04822 claims
AbbVieLinzess$571$12,47211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →